Cargando…

P1017: HARBOR: A PHASE 2/3 STUDY OF BLU-263 IN PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS AND MONOCLONAL MAST CELL ACTIVATION SYNDROME

Detalles Bibliográficos
Autores principales:	Castells, M., Scherber, R., Bhavsar, V., He, K., Akin, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430067/ http://dx.doi.org/10.1097/01.HS9.0000846936.51452.f2

Ejemplares similares

P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL
por: Gotlib, Jason, et al.
Publicado: (2023)

Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome
por: Kaakati, Rayan, et al.
Publicado: (2021)

Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches
por: Paiva, Marcelo L., et al.
Publicado: (2023)

COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms
por: Giannetti, Matthew P., et al.
Publicado: (2021)

Efficacy of Omalizumab in Indolent Systemic Mastocytosis
por: Slapnicar, Calum, et al.
Publicado: (2019)

Treatment of Indolent and Advanced Systemic Mastocytosis
por: Buonomo, Alessandro, et al.
Publicado: (2022)

P996: UTILITY OF KIT P.D816 IN MYELOID NEOPLASM WITHOUT DOCUMENTED SYSTEMIC MASTOCYTOSIS TO DETECT HIDDEN MAST CELLS IN BONE MARROW
por: Kim, D. H., et al.
Publicado: (2022)

Clinical presentation and markers of cutaneous versus systemic mastocytosis: the mastocytosis center at brigham and women's hospital in Boston
por: Kanamori, Kelly Yoshimi, et al.
Publicado: (2015)

COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
por: Bonadonna, Patrizia, et al.
Publicado: (2021)

P263: Infection control-uphill task in India
por: Rao, R, et al.
Publicado: (2013)

Indolent systemic mastocytosis in a patient with ileocolitis
por: Chrysakopoulos, Georgios, et al.
Publicado: (2014)

Delayed Diagnosis of Adult Indolent Systemic Mastocytosis
por: Mikkelsen, Carsten Sauer, et al.
Publicado: (2014)

Indolent systemic mastocytosis mimicking Crohn’s disease
por: Hadjivasilis, Alexandros, et al.
Publicado: (2019)

P994: HEDGEHOG PATHWAY INVOLVEMENT IN MASTOCYTOSIS DEVELOPMENT
por: Polivka, L., et al.
Publicado: (2022)

Role of Mast Cells in the Pathogenesis of Pruritus in Mastocytosis
por: KWIATKOWSKA, Dominika, et al.
Publicado: (2021)

Fisica e realtà.blu
por: Romeni, Claudio
Publicado: (2012)

Perch il cielo blu?
Publicado: (2009)

P1006: NEXT GENERATION SEQUENCING (NGS) IN PEDIATRIC MASTOCYTOSIS
por: Angi, A., et al.
Publicado: (2022)

Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study
por: Padilla, Brad, et al.
Publicado: (2021)

Indolent Systemic Mastocytosis Manifesting as Protracted Anaphylactic Shock
por: Chatterjee, Manidipam, et al.
Publicado: (2018)

Primary cicatricial alopecia associated with systemic indolent mastocytosis
por: Prasad, Sonya, et al.
Publicado: (2020)

DNA methylation profile in patients with indolent systemic mastocytosis
por: Górska, Aleksandra, et al.
Publicado: (2021)

Mastocytosis and Mast Cell Activation Disorders: Clearing the Air
por: Jackson, Clayton Webster, et al.
Publicado: (2021)

PReS-FINAL-1017: Antioxidant superoxide dismutase activity is elevated in jia but not associated with disease activity
por: Radziszewska, A, et al.
Publicado: (2013)

mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis
por: Rama, Tiago Azenha, et al.
Publicado: (2021)

Indolent systemic mastocytosis associated with light chain deposition disease
por: Sasaki, Kotaro, et al.
Publicado: (2012)

Diagnosis of indolent systemic mastocytosis in a patient with “seborrheic keratosis”
por: Moshref Razavi, Habib, et al.
Publicado: (2022)

Presumed mast cell choroidal infiltrate in aggressive systemic mastocytosis
por: Tran, Tu M., et al.
Publicado: (2020)

Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis
por: Reszka, Edyta, et al.
Publicado: (2021)

A Puzzling Mast Cell Trilogy: Anaphylaxis, MCAS, and Mastocytosis
por: Gülen, Theo
Publicado: (2023)

P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS
por: Mancini, M., et al.
Publicado: (2022)

An elusive case of systemic mastocytosis
por: Lee, JK, et al.
Publicado: (2010)

Hacking CD/DVD/Blu-ray for Biosensing
por: Hwu, Edwin En-Te, et al.
Publicado: (2018)

Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level
por: Selcuk, Ali, et al.
Publicado: (2021)

1017. Gut Microbiota Diversity and Beneficial Metabolite Production is Reduced in Liver Transplant Recipients and Associated with Post Operative Infection
por: Lehmann, Christopher J, et al.
Publicado: (2021)

Código BLU : código de prácticas para la seguridad de los operaciones de carga y descarga de graneleros.
Publicado: (2002)

P1038: CLINICOPATHOLOGIC AND MOLECULAR CORRELATES OF ORGAN DAMAGE ACROSS THE SPECTRUM OF ADVANCED SYSTEMIC MASTOCYTOSIS
por: Liang, E., et al.
Publicado: (2022)

P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
por: Lübke, Johannes, et al.
Publicado: (2023)

P1365: HUMAN CD117 AS AN IMMUNOTHERAPEUTIC TARGET IN PRECLINICAL MODELS OF ADVANCED SYSTEMIC MASTOCYTOSIS
por: Kaiser, Anne, et al.
Publicado: (2023)

Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF(©)
por: Taylor, Fiona, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2hpg2m7a0ib7vem9fsv5nfrcia